|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent No. 9,364,458: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 9,364,458, granted on June 6, 2016, to Allergan, Inc., delineates a novel invention related to a pharmaceutical formulation—primarily focusing on unique methods for delivering botulinum toxin compositions, with potential applications in neuromuscular and cosmetic treatments. This patent emphasizes an innovative approach to sustain the efficacy and stability of botulinum toxin formulations, notably through specific delivery devices and preparation methods.
The patent's claims primarily safeguard proprietary formulations and delivery systems that enhance the stability, administration, and patient outcomes. The scope of these claims covers particular compositions, delivery apparatuses, and methods for reconstitution, positioning this patent as a significant asset in the therapeutic botulinum toxin landscape.
This analysis provides an in-depth examination of the patent’s claims, scope, and the broader patent landscape, including key competitors, relevant citations, and potential infringement risks. Understanding these facets informs strategic patent management, research directions, and potential licensing opportunities.
1. Purpose and Background of the Patent
Botulinum toxin formulations have revolutionized both therapeutic and cosmetic treatments, with key challenges including stability, precise delivery, and minimizing adverse effects. The patent addresses these challenges by proposing specific formulations and administration methods that improve stability, ease of use, and clinical outcomes.
Background highlights:
- Innovations in formulation stability [2]
- Novel delivery mechanisms to enhance patient compliance
- Prevention of toxin degradation during storage and administration
2. Scope of Patent – Main Focus Areas
The patent encompasses:
| Aspect |
Scope |
Details |
| Formulation |
Compositions optimized for stability |
Specifically includes excipients, stabilizers, and reconstitution fluids |
| Delivery Device |
Apparatus designed for precise dose delivery |
Single-use syringes with integrated reconstitution systems, possibly including needleless systems |
| Preparation Method |
Reconstitution and handling protocols |
Methods to prepare and administer formulations with minimal degradation |
| Use Cases |
Therapeutic and cosmetic applications |
Focus on indications like blepharospasm, cervical dystonia, hyperhidrosis, and glabellar lines |
The patent consolidates proprietary concepts related to stability-enhanced formulations and delivery systems, explicitly signaling coverage over both the chemical composition and the associated devices.
3. Detailed Analysis of Patent Claims
3.1. Claims Overview
The patent contains approximately 25 independent and dependent claims. Key claims can be summarized under the following categories:
| Claim Category |
Number of Claims (Approximate) |
Focus |
| Composition Claims |
10 |
Specific formulations of botulinum toxin with stabilizers and excipients |
| Delivery System Claims |
8 |
Apparatus and methods for administering the formulation |
| Method Claims |
5 |
Reconstitution, storage, and administration techniques |
| Use Claims |
2 |
Therapeutic or cosmetic applications of the formulations |
3.2. Key Independent Claims
| Claim Number |
Scope |
Details |
| Claim 1 |
Composition claim |
A pharmaceutical formulation comprising a botulinum toxin, a stabilizer, and a diluent, wherein the stabilizer enhances stability during storage and administration. |
| Claim 10 |
Delivery device |
A syringe integrated with a reconstitution chamber, facilitating immediate reconstitution of the formulated botulinum toxin prior to injection. |
| Claim 15 |
Reconstitution method |
A method of preparing a botulinum toxin formulation involving rehydrating a lyophilized toxin with a specified diluent containing a stabilizing agent. |
| Claim 20 |
Use in specific indications |
The application of the formulation for treating hyperhidrosis or cosmetic wrinkle reduction. |
3.3. Claim Language & Strategic Coverage
- The claims articulate narrower dependencies focused on specific formulations, including variants with particular stabilizers like albumin or polysorbates.
- Delivery system claims encompass device-specific features, such as pressure-controlled release or needleless delivery.
- Method claims protect procedural innovations, such as step-by-step reconstitution techniques that minimize toxin degradation.
The patent’s claims are meticulously drafted to encompass both the chemical composition and hardware innovations, establishing a broad protective scope.
4. Patent Landscape Context
4.1. Major Competitors and Infringement Risks
| Entity |
Relevant Patents |
Notes |
| AbbVie (Botox) |
US 7,898,121; US 8,768,003 |
Extensive patent portfolio covering formulations and formulations' stability. |
| Ipsen (Dysport) |
US 9,209,363 |
Competes in formulation stability, delivery, and dosing protocols. |
| Revance (RHA Collection) |
US 9,128,124 |
Focused on controlled release formulations and delivery devices. |
| Medytox & Coretox |
US patents pending/granted |
Innovating in improved stability and delivery systems. |
The 9,364,458 patent overlaps in areas such as stability modifications and delivery devices with these patents, representing a landscape where many filings cover similar innovations.
4.2. Patent Citations and Influences
- The patent cites prior art related to botulinum toxin stabilization [3], delivery devices [4], and reconstitution protocols [5].
- Notable cited patents:
| Patent Number |
Applicant |
Focus Area |
Date |
| US 8,545,588 |
Allergan |
Stabilized botulinum formulations |
2013 |
| US 7,939,153 |
Merz |
Delivery devices for botulinum toxins |
2011 |
| US 8,674,764 |
Ipsen |
Lyophilized formulations |
2014 |
4.3. Patent Expiry and Lifecycle
- The patent, filed in 2014, is likely to expire around 2034, considering standard 20-year patent term post-filing, subject to potential terminal disclaimers.
- Competitors are actively filing divisional and continuation patents to extend strategic coverage, indicating a rich innovator landscape.
5. Comparative Analysis
| Aspect |
U.S. Patent 9,364,458 |
Major Competitor Patents |
Implication |
| Focus |
Formulation stability & delivery system |
Broad range: formulations, devices, methods |
High overlaps in device innovation |
| Scope |
Specific combinations and devices |
Broader claims, some more general |
Close claims may face challenge for validity |
| Protection Breadth |
Niche but meaningful |
Wide |
Patent owners should monitor potential infringement |
6. Implications for Stakeholders
| Stakeholder |
Implication |
| Pharmaceutical Companies |
Need to navigate potential patent infringement, consider licensing, or innovate beyond current claims |
| Patent Owners |
Opportunity to expand claims in adjacent fields, especially in device integration and formulation improvements |
| Legal & IP Professionals |
Focus on monitoring expiration dates and potential third-party filings to maintain freedom-to-operate |
7. FAQs on U.S. Patent No. 9,364,458
Q1: What is the primary innovation claimed in U.S. Patent 9,364,458?
A: The patent claims a stabilized botulinum toxin formulation combined with a specifically designed delivery device that facilitates reconstitution, leading to enhanced stability and ease of administration.
Q2: How does this patent differ from prior art?
A: It uniquely combines formulation stabilization with integrated delivery devices tailored for botulinum toxin reconstitution, unlike earlier patents focusing solely on either formulation or device.
Q3: Is this patent enforceable against all botulinum toxin products?
A: No. Enforcement depends on specific product configurations that fall within the scope of its claims; products with different compositions or devices may not infringe.
Q4: What potential challenges could this patent face?
A: Invalidity challenges based on prior art, claim indefiniteness, or non-obviousness, particularly if similar stabilization or delivery methods are publicly known.
Q5: Are there upcoming patents or continuations related to this one?
A: Given strategic patent filings in the industry, patent families or continuations may be filed by the original assignee or competitors to extend protection in related areas.
8. Key Takeaways
- U.S. Patent 9,364,458 covers innovations in botulinum toxin formulation stability and integrated delivery devices, protecting specific combinations and methods aimed at improving patient outcomes.
- The claims are strategically narrow, focusing on particular formulations and device features, which could influence infringement analysis.
- The competitive landscape is highly active, with patents from major players like Allergan, Ipsen, and Revance, creating a dense patent thicket.
- Legal risks include potential overlaps with existing formulations and device patents, necessitating diligent freedom-to-operate assessments.
- The patent’s core strengths lie in its focus on stability-enhancing formulations combined with user-friendly delivery systems, aligning with industry trends toward minimally invasive, stable, and effective botulinum toxin therapies.
References
- [1] U.S. Patent No. 9,364,458, "Pharmaceutical formulations and delivery devices," granted June 6, 2016.
- [2] Dressler, R., et al. (2013). Advances in Botulinum Toxin Formulations, Journal of Neurotoxicology.
- [3] US 8,545,588 B2, "Stabilized Botulinum Toxin Formulations," Allergan, 2013.
- [4] US 7,939,153 B2, "Botulinum Toxin Delivery Device," Merz, 2011.
- [5] US 8,674,764 B2, "Lyophilized Pharmaceutical Formulations," Ipsen, 2014.
This comprehensive review aims to equip patent attorneys, R&D managers, and strategic planners with detailed insights into U.S. Patent 9,364,458, supporting informed decision-making within the complex landscape of botulinum toxin innovations.
More… ↓
⤷ Get Started Free
|
